Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Intangibles (2024 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Intangibles for 2 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • Quarterly Intangibles rose 56.08% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.4 million through Dec 2025, up 56.08% year-over-year, with the annual reading at $7.4 million for FY2025, 56.08% up from the prior year.
  • Intangibles for Q4 2025 was $7.4 million at Madrigal Pharmaceuticals, down from $7.5 million in the prior quarter.
  • The five-year high for Intangibles was $7.5 million in Q3 2025, with the low at $4.5 million in Q2 2025.